Statements (76)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:analysis |
multiple sites
|
| gptkbp:analyzes |
gptkb:pertuzumab
gptkb:trastuzumab |
| gptkbp:associated_with |
HE R2-targeted therapy
|
| gptkbp:collaborated_with |
academic institutions
|
| gptkbp:completed |
gptkb:2014
|
| gptkbp:conducted |
multiple countries
|
| gptkbp:contributed_to |
FDA approval
patient care improvements guideline updates |
| gptkbp:depicted_in |
statistical significance
|
| gptkbp:ends_at |
pertuzumab improves outcomes
|
| gptkbp:examines |
combination therapy
patient demographics disease progression treatment protocols treatment combinations treatment safety |
| gptkbp:exhibited_at |
improved outcomes
|
| gptkbp:focuses_on |
treatment efficacy
HE R2-positive breast cancer |
| https://www.w3.org/2000/01/rdf-schema#label |
CLEOPATRA trial
|
| gptkbp:includes |
adverse events
metastatic breast cancer |
| gptkbp:influenced |
gptkb:municipality
research funding clinical practice breast cancer therapy |
| gptkbp:involves |
randomized controlled trial
|
| gptkbp:is_analyzed_in |
quality of life
treatment efficacy treatment response survival rates long-term effects treatment strategies adverse reactions |
| gptkbp:is_compared_to |
trastuzumab alone
|
| gptkbp:is_evaluated_by |
safety profile
|
| gptkbp:is_informed_by |
healthcare policies
future research future trials |
| gptkbp:is_involved_in |
multinational teams
multicenter collaboration |
| gptkbp:is_tested_for |
Phase III
|
| gptkbp:launched |
gptkb:2010
|
| gptkbp:led_to |
Dr. José Baselga
|
| gptkbp:notable_work |
gptkb:2015
|
| gptkbp:participants |
overall survival
progression-free survival |
| gptkbp:provides |
clinical evidence
insights into therapy data for meta-analyses evidence for combination therapy |
| gptkbp:provides_information_on |
systematic reviews
|
| gptkbp:published_by |
gptkb:The_New_England_Journal_of_Medicine
oncology journals |
| gptkbp:receives_funding_from |
gptkb:Genentech
|
| gptkbp:recruitment |
gptkb:philosopher
|
| gptkbp:reports_to |
treatment adherence
patient outcomes clinical outcomes medical conferences safety outcomes clinical significance clinicaltrials.gov |
| gptkbp:result |
gptkb:2012
gptkb:2014 significant benefit |
| gptkbp:sponsor |
gptkb:Roche
|
| gptkbp:student_enrollment |
800 participants
|
| gptkbp:used_in |
treatment guidelines
|
| gptkbp:utilizes |
biomarkers
placebo control |
| gptkbp:bfsParent |
gptkb:pertuzumab
|
| gptkbp:bfsLayer |
5
|